T cell therapy for nasopharyngeal carcinoma.

Item

http://www.wikidata.org/entity/Q42766336

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

T cell therapy for nasopharyngeal carcinoma.

@en

T cell therapy for nasopharyngeal carcinoma.

@nl

type

Item

label

T cell therapy for nasopharyngeal carcinoma.

@en

T cell therapy for nasopharyngeal carcinoma.

@nl

prefLabel

T cell therapy for nasopharyngeal carcinoma.

@en

T cell therapy for nasopharyngeal carcinoma.

@nl

P1476

T cell therapy for nasopharyngeal carcinoma

@en

P2093

A Gurrado

http://www.w3.org/2001/XMLSchema#string

G Ottonello

http://www.w3.org/2001/XMLSchema#string

G Quartuccio

http://www.w3.org/2001/XMLSchema#string

I Guido

http://www.w3.org/2001/XMLSchema#string

N Zavras

http://www.w3.org/2001/XMLSchema#string

P Guerini

http://www.w3.org/2001/XMLSchema#string

R Maccario

http://www.w3.org/2001/XMLSchema#string

S Secondino

http://www.w3.org/2001/XMLSchema#string

P2860

Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma

Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens

Adoptive cell transfer: a clinical path to effective cancer immunotherapy

Radiation and chemotherapy combination for nasopharyngeal carcinoma in children: Radiotherapy dose adaptation after chemotherapy response to minimize late effects.

Phase II trial combining mitomycin with 5-fluorouracil, epirubicin, and cisplatin in recurrent and metastatic undifferentiated carcinoma of nasopharyngeal type.

Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients.

Skeletal complications in pediatric oncology patients.

Dendritic cells transduced with an adenovirus vector encoding Epstein-Barr virus latent membrane protein 2B: a new modality for vaccination.

The interplay between Epstein-Barr virus and the immune system: a rationale for adoptive cell therapy of EBV-related disorders

Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer.

P304

341-346

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.7150/JCA.2.341

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-06-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21716854

http://www.w3.org/2001/XMLSchema#string

P932

3119400

http://www.w3.org/2001/XMLSchema#string